Author

Ranran Wu

The University of Texas MD Anderson Cancer CenterPrimary ORCID profile (0000-0002-6276-1425 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Ranran WuiD1 paper · University of Pennsylvania

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:metabolomics· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Ana Vilchis Celis· 1 shared Anirban MaitraiD· 1 shared Benson Chellakkan SelvanesaniD· 1 shared Brian W. Wolpin· 1 shared Cason Haffner· 1 shared Daniela Rodriguez-Perera· 1 shared Ehsan IrajizadiD· 1 shared Eugene Koay· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ana Vilchis Celis

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma

Yihui Chen, Cason Haffner, Benson Chellakkan Selvanesan, Ranran Wu, Riccardo Ballarò, Ana Vilchis Celis, Mingxin Zuo, LaNisha L. Patterson, Michael Adofo, Jody Vykoukal, Ricardo A. Léon-Letelier, Rongzhang Dou, Soyoung Park, Yining Cai, Daniela Rodriguez-Perera, , Johannes Francois Fahrmann

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

bioRxiv · Oct 6, 2026 · PreprintCancer Biology